Table 2. Mitochondrial medications and supplements*.
Medication | Dosage (pediatric) | Dosage (adult) | Monitoring | Adverse effects | Comments |
---|---|---|---|---|---|
CoQ10 as ubiquinol (preferred) | 2–8 mg/kgpo daily divided in two doses | 50–600 mg po daily | May obtain pretherapy level and monitor CoQ1 level in leukocytes or plasma | Wakefulness, sleep disruption; may reduce warfarin concentration | Solubilized bioavailable formulation preferred. Absorption may be improved when taken with meals |
CoQI0as ubiquinone | 10–30 mg/kg po daily divided in 2 doses | 300–2400 mg po daily divided 2–3 times a day | May obtain pretherapy level and monitor CoQ10evel in leukocytes or plasma | Wakefulness, sleep disruption; may reduce warfarin concentration | Less potent than ubiquinol and less well absorbed; solubilized bio available formulation preferred. Absorption may be improved when taken with meals |
Riboflavin (B2) | 50–400 mg po daily | 50–400 mg po daily | Not usually done | High doses may cause anorexia and nausea | Changes urine color and smell; effects may be minimized by giving at bedtime |
L-Creatine | 0.1 g/kg po daily; maximum 10 g/d | 5 g po daily, given 1–2 times per day | Renal function | GI upset | Primarily used in myopathy patients, though evidence exists for routine use in all mitochondrial disease patients; converted to creatinine in the gut |
L-Arginine | Acute stroke: 500 mg/kg IV per day for 1 –3 days; Maintenance: 150–300 mg/kgpo or IV daily divided 2–3 times a day | Acute stroke: 500 mg/kg IV per day for 1–3 days; Maintenance: 150–300 mg/kg po or IV daily divided 2–3 times a day | Plasma arginine in amino acid profile | Hypotension (with IV loading), hyponatremia, headache, nausea, diarrhea. Myelinolysis reported with high dose in single case | Used with metabolic strokes, especially in MELAS or in those with low-normal plasma arginine; citrulline is used in urea cycle defects as an alternative to arginine |
L-Carnitine | 10–100 mg/kg per day IV or po divided 3 times a day | 100–1000 mg per dose, given IV or po 2–3 times a day | Pretherapy free and total plasma carnitine levels | GI upset, fishy odor (due to bacterial degradation; may be improved with antibiotic). Reports of cardiac rhythm disturbances in long-chain fatty acid oxidation defects | FDA-approved for metabolic diseases; available as prescription generic and brand. Only 10%–20% absorbed. Acetyl-carnitine is an alternative |
B50or B100 (B vitamin complexes) | 1 tab po given 1–2 times a day | 1 tab po given 1–2 times a day | Not usually done | Toxic neuropathy may occur with chronic use of larger doses than recommended | Poorly palatable |
Vitamin E | 1–2 IU/kg po daily | 100–200 IU po daily | Not usually done | Possible adverse cardiac risks at doses > 400 IU/d | Absorption may be improved when taken with meals |
Vitamin C | 5 mg/kg po daily | 50–200 mg po daily | Not usually done | Increases iron absorption; high doses may cause renal insufficiency (single case report) | Easily absorbed water-soluble vitamin |
Alpha-lipoic acid | 50–200 mg/d | 50–200 mg/d | Not usually done | None known | None |
Folinic acid as leucovorin, containing both D and L isomers | 0.5–1.5 mg/kg po daily, given 1–2 times per day (higher doses are used in folinic acid-responsive epilepsy) | 2.5–25 mg po daily given 1–2 times per day | May assess spinal fluid folate and plasma/urine pipecolic acid | Rash and pruritus | Cerebral folate can also be replenished with Isovorin (L-isomer, active form) or 5-methyl-tetrahydrofolate (Deplin), the natural transport form of folate across the blood-brain barrier. Consider for patients with symptom worsening or with proven cerebral folate deficiency |
CoQ10 and a B vitamin are the most commonly used medications in a starting “mitochondrial treatment cocktail.”
CoQ10—coenzyme Q10; FDA—US Food and Drug Administration; GI—gastrointestinal; IV—intravenous; MELAS—mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes; po—by mouth.